RxDoctor Payments Data

Sunitha Nagubilli, MD

Family Medicine · Union, SCNPI 1225325293

Payments from drug & device makers

$770in general payments, 2019–2025

Across 45 payments — averaging $17.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$288
  • Amgen$57
  • Astellas Pharma US Inc$53
  • Dexcom, Inc.$50
  • Abbott$42
  • Novo Nordisk$39
  • plus $241 from 9 others

What the payments were for

  • Food & beverage$770100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$770 in reported general payments places this provider in the 55th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$12,282
Medicare patients
49
Services billed
140

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban123$115,528
OzempicSemaglutide57$86,366
FarxigaDapagliflozin Propanediol100$84,092
JanuviaSitagliptin Phosphate62$68,571
JardianceEmpagliflozin69$63,825
Trelegy ElliptaFluticasone/Umeclidin/Vilanter81$62,959
TrulicityDulaglutide49$53,633
XareltoRivaroxaban29$26,807
Breo ElliptaFluticasone/Vilanterol45$21,594
MyrbetriqMirabegron34$17,793
Lantus SolostarInsulin Glargine,hum.Rec.Anlog72$12,843
RybelsusSemaglutide13$12,622
Soliqua 100-33Insulin Glargine/Lixisenatide13$10,683
SymbicortBudesonide/Formoterol Fumarate20$8,163
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$7,977

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Dilantin$32$119,104140 claims
Novo NordiskOzempic, Rybelsus$39$98,98870 claims
GSKTrelegy Ellipta, Breo Ellipta$33$84,553126 claims
MerckJanuvia$16$68,57162 claims
Johnson & JohnsonXarelto$30$26,80729 claims
Astellas Pharma US IncMyrbetriq$53$17,79334 claims
AbbVieSynthroid$288$1,78744 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Union

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →